Mao Y M
Renji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai Institute of Digestive Disease, Shanghai Research Center of Fatty Liver Disease, Shanghai 200001, China.
Zhonghua Gan Zang Bing Za Zhi. 2024 Apr 20;32(4):312-317. doi: 10.3760/cma.j.cn501113-20230829-00077.
Drug can cause almost all known types of acute, subacute, and chronic liver injuries. Drug-induced liver injury (DILI) is an important cause of unexplained liver injury in clinical practice. Correct diagnosis of DILI is challenging due to lack of specific diagnostic biomarkers, especially in patients with pre-existing liver disease and multiple concomitant drugs. A comprehensive understanding of the risk factors, clinical features, and prognosis of liver injury caused by different drugs will help physicians to recognize, diagnose, and manage it timely. Although the guideline was developed based on evidence-based medicine provided by the latest studies, there is limited high-quality evidence in the field of DILI. Therefore, this guideline should be interpreted with caution, and physicians should adopt an optimal diagnostic and therapeutic strategy for individual patients within the framework of the guideline.
药物可导致几乎所有已知类型的急性、亚急性和慢性肝损伤。药物性肝损伤（DILI）是临床实践中不明原因肝损伤的重要原因。由于缺乏特异性诊断生物标志物，DILI的正确诊断具有挑战性，尤其是在患有既往肝病和多种合并用药的患者中。全面了解不同药物所致肝损伤的危险因素、临床特征及预后，将有助于医生及时识别、诊断和处理。尽管本指南是基于最新研究所提供的循证医学制定的，但在DILI领域高质量证据有限。因此，对本指南的解读应谨慎，医生应在指南框架内针对个体患者采用最佳诊断和治疗策略。
